ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 22.7 TWD -1.09% Market Closed
Market Cap: 17.9B TWD

P/E
Price to Earnings

44.9
Current
64.7
Median
20.5
Industry
Lower than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
44.9
=
Market Cap
17.9B TWD
/
Net Income
399.4m TWD
Earnings Growth PEG
TW
ScinoPharm Taiwan Ltd
TWSE:1789
Average P/E: 30.8
44.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
74.9
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
23.3
19%
1.2
CH
Roche Holding AG
SIX:ROG
21.4
16%
1.3
US
Merck & Co Inc
NYSE:MRK
13.8
17%
0.8
UK
AstraZeneca PLC
LSE:AZN
33.1
36%
0.9
CH
Novartis AG
SIX:NOVN
19.1
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.5
29%
0.6

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
67.4
2-Years Forward
P/E
57.1
3-Years Forward
P/E
N/A